期刊文献+

miR-155-5p在肝细胞癌中的表达及其作用机制 被引量:5

The role of miR-155-5p in liver cancer and its mechanism
下载PDF
导出
摘要 目的:初步探讨microRNA-155-5p(miR-155-5p)在原发性肝细胞癌(HCC)中的表达及作用,验证其对SRY核转录因子6(SOX6)的可能靶向调控作用,为HCC的靶向治疗提供新理论依据。方法:收集2017年1月至2019年10月在四川大学华西医院金堂医院胆外科接受手术切除的26例HCC患者的肿瘤组织和癌旁组织的样本。采用实时定量PCR(qRT-PCR)检测miR-155-5p和SOX6在不同HCC细胞系的表达情况;采用CCK-8法、划痕实验及Transwell实验观察miR-155-5p对HepG2细胞增殖、迁移和侵袭能力的影响;采用双荧光素报告基因验证miR-155-5p对SOX6的靶向调控作用。结果:与癌旁组织/正常细胞相比,肿瘤组织/HCC系细胞中miR-155-5p表达明显升高(P<0.01),而SOX6的表达量与癌旁组织相比显著下降(P<0.01);与miR-155-5p+NC组相比,miR-155-5p+SOX6组细胞凋亡率显著上升,细胞增殖,迁移以及侵袭明显抑制(P<0.05),此外,与Mut-SOX6-3转染的细胞相比,miR-155-5p和WT-SOX6-3'UTR共转染可明显抑制萤光素酶活性(P<0.01)。结论:miR-155-5p在HCC中高表达,且可促进HepG2细胞增殖、迁移和侵袭,其机制可能与miR-155-5p通过调控SOX6的表达来影响肝细胞癌的进展有关。 Objective:To Preliminary study on the expression and role of microRNA-155-5p(miR-155-5p)in Hepatocellular carcinoma(HCC),and verify its possible targeted regulation of SRY nuclear transcription factor 6(SOX6).Targeted therapy provides new theoretical basis.Methods:Samples of tumor tissues and adjacent tissues from 26 patients with primary hepatocellular carcinoma(HCC)who underwent surgical resection at Jintang Hospital of West China Hospital of Sichuan University from January 2017 to October 2019 were collected.Real-time quantitative PCR(qRT-PCR)was used to detect the expression of miR-155-5p and SOX6 in HCC and different HCC cell lines;CCK-8 method,scratch test and Transwell test were used to observe the proliferation of miR-155-5p on HepG2 cells Effect of miR-155-5p on SOX6 by dual luciferin reporter gene.Results:Compared with adjacent tissues/normal cells,the expression of miR-155-5p in tumor tissues/HCC cells was significantly increased(P<0.01),while the expression level of SOX6 was significantly decreased compared with adjacent tissues(P<0.01).Compared with miR-155-5p+NC,the apoptosis rate of miR-155-5p+SOX6 group increased significantly,and cell proliferation,migration and invasion were significantly inhibited(P<0.01).In addition,compared with Mut-SOX6-3 transfected cells,Co-transfection of miR-155-5p and WT-SOX6-3'UTR could significantly inhibit luciferase activity(P<0.01).Conclusion:miR-155-5p is highly expressed in HCC and can promote the proliferation,migration and invasion of HepG2 cells.The mechanism may be related to miR-155-5p affecting the progression of hepatocellular carcinoma by regulating the expression of SOX6,this provides new targets for the treatment of liver cancer.
作者 喻茂文 黄淑彬 陈永刚 YU Mao-wen;HUAMG Shu-bin;CHEN Yong-gang(Laboratory Medicine,Jintang Hospital,West China Hospital of Sichuan University,Chengdu Sichuan,610400,China;不详)
出处 《中西医结合肝病杂志》 CAS 2021年第2期130-134,共5页 Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
基金 国家重点基础研究发展计划(No.2015CB755402-108)。
关键词 肝细胞癌 微小RNA 细胞增殖 细胞迁移 hepatocellular carcinoma microRNA cell proliferation cell migration
  • 相关文献

参考文献2

二级参考文献111

  • 1Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma.Lancet 2012; 379: 1245-1255 [PMID: 22353262 DOI: 10.1016/S0140-6736(11)61347-0].
  • 2Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma:clinical frontiers and perspectives. Gut 2014; 63: 844-855 [PMID:24531850 DOI: 10.1136/gutjnl-2013-306627].
  • 3European Association For The Study Of The Liver, EuropeanOrganisation For Research And Treatment Of Cancer. EASLEORTCclinical practice guidelines: management of hepatocellularcarcinoma. J Hepatol 2012; 56: 908-943 [PMID: 22424438 DOI:10.1016/j.jhep.2011.12.001].
  • 4Marrero JA, Kudo M, Bronowicki JP. The challenge of prognosisand staging for hepatocellular carcinoma. Oncologist 2010; 15Suppl 4: 23-33 [PMID: 21115578 DOI: 10.1634/theoncologist.2010-S4-23].
  • 5Olthoff KM, Forner A, Hübscher S, Fung J. What is the beststaging system for hepatocellular carcinoma in the setting of livertransplantation- Liver Transpl 2011; 17 Suppl 2: S26-S33 [PMID:21656653 DOI: 10.1002/lt.22352].
  • 6Maida M, Orlando E, Cammà C, Cabibbo G. Staging systemsof hepatocellular carcinoma: a review of literature. World JGastroenterol 2014; 20: 4141-4150 [PMID: 24764652 DOI:10.3748/wjg.v20.i15.4141].
  • 7Subramaniam S, Kelley RK, Venook Ap. A review of hepatocellularcarcinoma (HCC) staging systems. Chin Clin Oncol 2013; 2: 33Available from: URL: http: //www.thecco.net/article/view/2528.
  • 8Okuda K, Obata H, Nakajima Y, Ohtsuki T, Okazaki N, Ohnishi K.Prognosis of primary hepatocellular carcinoma. Hepatology 1984; 4:3S-6S [PMID: 6319264].
  • 9Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N,Hasegawa H, Nakajima Y, Ohnishi K. Natural history ofhepatocellular carcinoma and prognosis in relation to treatment.Study of 850 patients. Cancer 1985; 56: 918-928 [PMID: 2990661].
  • 10A new prognostic system for hepatocellular carcinoma: aretrospective study of 435 patients: the Cancer of the Liver ItalianProgram (CLIP) investigators. Hepatology 1998; 28: 751-755[PMID: 9731568].

共引文献14

同被引文献48

引证文献5

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部